Day One

Wednesday 17th April 2024

8:00 am Check In, Morning Coffee & Light Breakfast

8:55 am Chair’s Opening Remarks

Uncovering New Targetable Pathways in Inflammatory-Mediated Disease: Forming the Basis for Developing Safe & Effective Therapies

9:00 am Unraveling New Mechanisms in Itch from Targeting Type 2 Inflammation


  • Understanding shared and unique characteristics of AD, PN and CSU
  • How type 2 inflammation contributes to neuroimmune dysregulation 
  • Potential for IL-4Ra antagonism to reduce itch in chronic inflammatory skin diseases.

9:30 am Topical Biologics for the Treatment of Inflammatory Disorders Including Pruritus, AD, & Acne


• Discussion of the drug development evolution of a first-in-class therapy

• Results from previous Phase 2 studies

• Roadmapping what is next to bring these novel therapeutics to market

10:00 am Morning Break & Speed Networking


Meet and connect with your peers in this dedicated networking session

11:00 am Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology

  • Tamar Ben Yedidia CSO and clinical management, Scinai Immunotherapeutics
  • Michael Schön Professor and Chairman, Department of Dermatology, Venereology & Allergology, University Medical Center Goettingen


• Speaking to preclinical study design to evaluate anti-interleukin 17 NanoAbs as a treatment for plaque psoriasis, which showed the downregulation of psoriasis molecular markers

• Leveraging 3D biologic skin models to mimic the structure of human skin to suggest NanoAbs’ therapeutic potential

• Demonstrating the potential for a systemic novel approach with higher affinity for IL-17F isoform to improve treatment efficacy for patients with psoriasis

Biomarkers in Dermatology: Building Better Patient Population Insights Into Drug Development Strategy Planning

11:30 am Biomarker-Driven Drug Development in Dermatology


• How leveraging and integrating methodologies, including RNA sequencing and multiomics approaches can verify drug pharmacodynamics, demonstrating efficacy and safety through biomarkers

• Investigator-initiated studies with approved drugs to validate novel endpoints

• Deep-phenotyping of patients with inflammatory skin diseases for stratification and improved disease understanding

• Case study with anti-IL-23 therapy for psoriasis, presenting recent outcomes using a technology driven approach

12:00 pm Lunch Break


Take this chance to meet the expert speakers, connect with your peers and explore our exhibition hall to meet fresh and familiar faces or even your next partner!

1:00 pm Disease Modification in Dermatology: A Novel, First in Class Targeted Therapy for the Non-Immunosuppressive Treatment of Pemphigus & Stevens-Johnson/Toxic Epidermal Necrolysis syndrome


  • Development of a human monoclonal antibody against Fas ligand (PC111) that plays a major role in the pathogenesis of pemphigus and Stevens-Johnson/Toxic Epidermal Necrolysis syndrome
  • Sharing recent data demonstrating targeted therapy, that acts downstream of the immune system, highly differentiates from currently used potent immunosuppressors, with a good safety profile, meeting patients’ satisfaction
  • PC111 will be the first targeted therapy for Stevens-Johnson/Toxic Epidermal Necrolysis syndrome, acute and deadly diseases for which no approved drug exists

1:30 pm AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials


• Standardised high quality mobile skin imaging

• Smart skin imaging data and objective image analysis

Machine learning and AI powered decision support in Psoriasis, Hidradenitis and more disease areas

New digital skin biomarker and endpoints in clinical R&D and post marketing 

2:00 pm Afternoon Networking Break

Optimising Drug Delivery to Target Sites with Improved Stability & Bioavailability

2:45 pm Panel Session : Route of Administration & Formulations: How Can We Improve?


Delving into the complexities of selecting appropriate routes of administration and formulation strategies, learn expert takes on:

• How can biopharma better formulate drugs to effectively bypass or overcome the skin’s barrier function?

• What’s needed, from a drug delivery system perspective, to ensure optimal therapeutic outcomes and reduce potential side efects?

• What do biopharma developing therapeutics for immune-mediated dermatological conditions in dermatology need to consider in relation to drug route of administration across small molecule, biologic and mAb therapies?

• How can industry improve to accelerate the development of orally administered drugs?

3:30 pm Detailing Hedgehog-Signalling Inhibition as a Promising Target for Unmet Needs in the Dermatology Universe

  • Ofer Toledano Vice President - Research & Development, Sol Gel Technologies


• Exploring the mechanism of Patidegib a hedgehog inhibitor (HHI) blocker, preventing new basal cell carcinomas in Gorlin Syndrome

• Current data showcasing the potential of this mechanism and highlighting the benefits of topical HHIs over oral HHIs

Beyond Dermatology: Realising Opportunities for Disease with Inflammatory Components

4:00 pm Panel Session : Unlocking Synergies: Extending Dermatological Drug Development Insights to Address Broader Inflammatory Diseases


Gain insights into the extension of knowledge from immuno-dermatological drug development to encompass a broader range of inflammatory diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease and more:

• How can advancements in our mechanistic understanding of dermatological drug development interactions targeting inflammatory pathways be leveraged to benefit patients with other inflammatory diseases?

• What are the key challenges in translating dermatological drug discoveries into therapies for broader inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease?

• How can we ensure that cross-pollination efforts align with the diverse needs and experiences of patients with various inflammatory conditions?

• What strategies and initiatives can facilitate greater collaboration and knowledge sharing in the field of dermatology and broader inflammatory diseases?

• How can these advancements in precision medicine and biomarker development in dermatology be extended to identify patient populations in other inflammatory diseases who are most likely to benefit from cross-pollinated therapies, ensuring more targeted treatment approaches?

Moderated by: Nidhi Malhotra, Principal Scientist, MSD

4:45 pm Chair’s Closing Remarks & End of Day One